Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.53 |
| ▸ | JAK1 | P23458 | 10/20 | 0.53 |
| ▸ | JAK3 | P52333 | 10/20 | 0.53 |
| ▸ | TYK2 | P29597 | 3/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | LTK | P29376 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.53 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL100037 | 0.95 | JAK2 (0.49) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL2435395 | 0.94 | JAK2 (0.54) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL101390 | 0.92 | JAK2 (0.55) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL100672 | 0.91 | JAK2 (0.53) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL100976 | 0.91 | JAK3 (0.58) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL99920 | 0.91 | JAK2 (0.50) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL101804 | 0.91 | JAK2 (0.55) | JAK2JAK1JAK3TYK2DAPK3 | |
| SCHEMBL101362 | 0.90 | JAK2 (0.53) | JAK2JAK1JAK3TYK2DAPK3 | |
| Trifluoroacetic Acid SCHEMBL3451289 | 0.89 | JAK2 (0.50) | JAK2JAK1JAK3TYK2DAPK3 | |
| Trifluoroacetic Acid SCHEMBL100884 | 0.88 | JAK2 (0.48) | JAK2JAK1JAK3TYK2DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343299-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2348023-B9 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORP (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2343299-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-11-04 | — | — | EP | claimed |
| EP-2348023-B1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORP (US) | 2015-05-06 | — | — | EP | claimed |
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | claimed |
| EP-2474545-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-07-11 | — | — | EP | claimed |
| EP-2455382-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2426129-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-03-07 | — | — | EP | claimed |
| EP-1966202-B1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2011-09-21 | — | — | EP | claimed |
| EP-2348023-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-27 | — | — | EP | claimed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | claimed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | claimed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | claimed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343298-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | JAK2 4/4885JAK1 1/4885JAK3 2/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.